Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time ...
DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...
In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 ...
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q4 2025 Earnings Call Transcript February 20, 2026 Operator: Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care Fourth Quarter 2025 ...
In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...
Insulet’s Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE).
Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the ...
DexCom reported worldwide revenue of $1.26 billion versus $1.11 billion a year earlier, marking 13% reported growth and 12% organic. U.S. Q4 revenue climbed 11% year over year to $892 million, while ...
DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...
Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.
Zacks Investment Research on MSN
Dexcom stock falls despite Q4 earnings beat, G7 rollout drives growth
DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results